Abstract
The title compound, [ZnCl2(C13H11N3)]·C3H7NO, crystallized in the monoclinic crystal system in space group P21/n. The asymmetric unit contains one neutral complex mol-ecule, which consists of a zinc ion, a bidentate ligand, and two chlorido ligands with di-methyl-formamide monosolvate. The ligand has two moieties, a benzimidazole and an aniline group. The benzimidazole and aniline planes are not coplanar, subtending a dihedral angle of 18.24 (8)°. The Zn(II) ion shows distorted tetra-hedral geometry, being coordinated by an imidazole N atom, the aniline N atom, and two chlorido ligands. The packing features N-H⋯O, N-H⋯Cl, C-H⋯Cl hydrogen bonding.
Highlights
The asymmetric unit contains one neutral complex molecule, which consists of a zinc ion, a bidentate ligand, and two chlorido ligands with dimethylformamide monosolvate
The asymmetric unit of the title complex (Fig. 1) contains one neutral complex molecule, which consists of one central zinc ion, one bidentate ligand, and two chlorido ligands with dimethylformamide solvent
The complex is a four-coordinated system by one imidazole nitrogen atom N2, one aniline nitrogen atom N1, and two chlorido ligands
Summary
Benzimidazoles as organic ligands have attracted interest with regard to the synthesis of metal–organic frameworks, because of their coordination abilities to metal ions, and their significant potential applications in biological systems (Ahmad & Bharadwaj; 2013; Sharma et al, 2016; Gu et al, 2017). Benzimidazole compounds and their metal complexes have been found to show diverse biological activity (Podunavac-Kuzmanovic & Cvetkovic, 2010), including inhibition against enteroviruses (Xue et al, 2011) and potent antitumor activity (Galarce et al, 2008). Symmetry codes: (i) Àx þ 12; y þ 12; Àz þ 12; (ii) Àx þ 1; Ày þ 2; Àz þ 1; (iii) x þ 12; Ày þ 32; z À 12
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have